검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | SG (Sacituzumab Govitecan, Sacituzumab Govitecan (SG)) Gilead / Immunomedics·Urothelial Cancer ORR 44%·t½ 24 h |
|---|---|
Overview Program | Sacituzumab Govitecan (SG) |
Overview Company | Gilead / Immunomedics |
Overview Modality | ADC |
Overview Target | Urothelial Cancer |
Overview Indication | Urothelial Carcinoma; Muscle-invasive Bladder Cancer |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | targets, signaling pathway |
MoA Biomarker | eGFR, and low |
PK/PD Half-life | 24 h |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | Pharmacodynamic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Mechanisms for Mineralocorticoid-Driven Age-Related Hypertension: Potential Therapeutic Role of Mineralocorticoid Receptor Antagonists and Aldosterone Synthase Inhibitors.. Hypertension prevalence rises dramatically with advancing age, is not well controlled with current therapy, and contributes substantially to cardiovascular, renal, and neurological disorders that are common in the elderly. The … |
Toxicology CRS | 6.8% |
Clinical Primary efficacy | ORR 44% |
Clinical ORR | 44.0% |
Clinical Result source | ClinicalTrials.gov NCT04916002 |
Clinical Data Tier / Score | A · 49 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 18일 (8일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | SG (Sacituzumab Govitecan, Sacituzumab Govitecan (SG)) Gilead / Immunomedics·Urothelial Cancer ORR 44%·t½ 24 h |
|---|---|
Overview Program | Sacituzumab Govitecan (SG) |
Overview Company | Gilead / Immunomedics |
Overview Modality | ADC |
Overview Target | Urothelial Cancer |
Overview Indication | Urothelial Carcinoma; Muscle-invasive Bladder Cancer |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | targets, signaling pathway |
MoA Biomarker | eGFR, and low |
PK/PD Half-life | 24 h |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | Pharmacodynamic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Mechanisms for Mineralocorticoid-Driven Age-Related Hypertension: Potential Therapeutic Role of Mineralocorticoid Receptor Antagonists and Aldosterone Synthase Inhibitors.. Hypertension prevalence rises dramatically with advancing age, is not well controlled with current therapy, and contributes substantially to cardiovascular, renal, and neurological disorders that are common in the elderly. The … |
Toxicology CRS | 6.8% |
Clinical Primary efficacy | ORR 44% |
Clinical ORR | 44.0% |
Clinical Result source | ClinicalTrials.gov NCT04916002 |
Clinical Data Tier / Score | A · 49 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 18일 (8일 전) |
추천 비교
추천 비교